February 21, 2025

Filgotinib Shows Long-Term Safety in RA Patients

Filgotinib was well-tolerated over 8 years in rheumatoid arthritis patients, with low incidences of serious adverse events.

Conexiant

February 14, 2025

Study: Patients Trust Female Docs Less

Study findings and an interview with the lead investigator.

Conexiant

February 11, 2025

Type I IFN Score Predicts lcSSc Progression

High IFN score patients had a 5.5x higher risk of disease progression in lcSSc, researchers report.

Conexiant

February 11, 2025

Rare Pulmonary Lesions in CNO Show Favorable Outcomes

Pulmonary lesions in chronic nonbacterial osteomyelitis are rare and often asymptomatic, with most resolving over time, researchers report.

Conexiant

February 07, 2025

Hematologic Indicators Linked to Alopecia Areata Severity

Researchers analyze hematological ratios in alopecia areata severity assessment.

Conexiant

February 05, 2025

FDA Approves Tocilizumab Biosimilar

FDA approves AVTOZMA after phase III trial confirms equivalence in efficacy, safety, and pharmacokinetics for RA and other inflammatory conditions.

Conexiant

February 03, 2025

Key Comorbidities Elevate Risk of Severe Alopecia Areata

Study finds bronchial asthma, dermatitis, and thyroiditis significantly increase risk for early-onset, severe, and prolonged alopecia areata.

Conexiant

January 29, 2025

Fracture Infection Treatment: Oral vs Intravenous Data

A trial compared oral versus intravenous antibiotics for fracture-related infections.

Conexiant

January 29, 2025

JIA Uveitis: 68% Relapse After Stopping Adalimumab

A multicenter RCT of 87 patients with juvenile idiopathic arthritis-associated uveitis found that discontinuing adalimumab led to significantly higher treatment failure rates compared to continued therapy, though all patients who experienced failure regained control after restarting treatment.

Conexiant